secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2025-10-28T23:59:59+00:00
Accession:  0001171843-25-006690
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Edesa Biotech reports positive Phase 3 results for paridiprubart in ARDS; 28-day mortality reduced 13% absolute
--------------------------------------------------------------------------------

- Paridiprubart + SOC reduced 28-day mortality to 39% vs 52% placebo (n=104; p<0.001): 13% absolute improvement, 25% relative risk reduction.
- Durable survival benefit at 60 days: 46% vs 59% mortality (p=0.003); 13% absolute improvement, 22% relative risk reduction.
- Paridiprubart arm showed 41% higher relative rate of clinical improvement (≥2-point WCSS improvement at Day 28; p=0.032).
- Safety data from >275 subjects: paridiprubart generally well-tolerated, consistent with prior profile.
- Paridiprubart also in U.S. government 'Just Breathe' study; program funded by Government of Canada's Strategic Innovation Fund.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000117184325006690/0001171843-25-006690-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000117184325006690/f8k_102825.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-006690

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer